Successful Dose De-Escalation of Infliximab in Rheumatoid Arthritis Patients with Stable Low Disease Activity and Treatment

被引：0
|
作者：
van der Maas, Aatke
den Broeder, Alfons
van den Hoogen, Frank H. J. [1 ]
Van Riel, Piet [2 ]
van den Bemt, Bart J. F.
机构：
[1] Sint Maartensklini, Dept Rheumatol, Nijmegen, Netherlands
[2] Radboud Univ Nijmegen, Med Ctr, NL-6525 ED Nijmegen, Netherlands
来源：
ARTHRITIS AND RHEUMATISM | 2011年 / 63卷 / 10期
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
1700
引用
收藏
页码：S666 / S666
页数：1
相关论文
共 50 条
  • [1] Prediction of dose escalation for rheumatoid arthritis patients under infliximab treatment
    Van Looy, Stijn
    Cruyssen, Bert Vander
    Meeus, Jeroen
    Wyns, Bart
    Westhovens, Rene
    Durez, Patrick
    Van den Bosch, Filip
    Vastesaeger, Nathan
    Geldhof, Anja
    Boullart, Luc
    De Keyser, Filip
    ENGINEERING APPLICATIONS OF ARTIFICIAL INTELLIGENCE, 2006, 19 (07) : 819 - 828
  • [2] Outcomes of infliximab dose escalation in patients with rheumatoid arthritis
    Cohen, Stanley B.
    Kremer, Joel M.
    Dandreo, Kimberly J.
    Reed, George W.
    Magner, Robert
    Shan, Ying
    Kafka, Shelly
    DeHoratius, Raphael J.
    Ellis, Lorie
    Parenti, Dennis
    CLINICAL RHEUMATOLOGY, 2019, 38 (09) : 2501 - 2508
  • [3] Outcomes of infliximab dose escalation in patients with rheumatoid arthritis
    Stanley B. Cohen
    Joel M. Kremer
    Kimberly J. Dandreo
    George W. Reed
    Robert Magner
    Ying Shan
    Shelly Kafka
    Raphael J. DeHoratius
    Lorie Ellis
    Dennis Parenti
    Clinical Rheumatology, 2019, 38 : 2501 - 2508
  • [4] Dose escalation of infliximab in rheumatoid arthritis
    Haraoui, B
    Cameron, L
    Ouellet, M
    White, B
    JOURNAL OF INVESTIGATIVE DERMATOLOGY, 2005, 124 (04) : A6 - A6
  • [5] DISEASE ACTIVITY IN ESCALATION OR DE-ESCALATION OF DOSAGE OF TOFACITINIB IN RHEUMATOID ARTHRITIS PATIENTS - THE FIRST RESULTS OF RUSSIAN NATIONAL REGISTER OF PATIENTS WITH RHEUMATOID ARTHRITIS TREATED WITH TOFACITINIB
    Gaydukova, Inna
    Mazurov, V.
    Vasilenko, Elizaveta
    Zhilyaev, Evgeniy
    Poncratov, Vyacheslav
    Sorotskaya, Valentina
    Lukina, Galina
    Fomina, Oxana
    Babaeva, Aida
    Lapkina, N.
    Misiyuk, Anna
    Pavlova, A.
    Nasonov, Evgeny
    ANNALS OF THE RHEUMATIC DISEASES, 2019, 78 : 746 - 746
  • [6] Double-blinded infliximab dose escalation in patients with rheumatoid arthritis
    Rahman, Mahboob U.
    Strusberg, Ingrid
    Geusens, Piet
    Berman, Alberto
    Yocum, David
    Baker, Daniel
    Wagner, Carrie
    Han, John
    Westhovens, Rene
    ANNALS OF THE RHEUMATIC DISEASES, 2007, 66 (09) : 1233 - 1238
  • [7] COMPARISON OF DOSE ESCALATION AND COSTS OF DOSE ESCALATION BETWEEN PATIENTS WITH RHEUMATOID ARTHRITIS INITIATING BIOLOGIC TREATMENT WITH ETANERCEPT, ADALIMUMAB, OR INFLIXIMAB
    Garces, K.
    Thorne, C.
    Boire, G.
    Chow, A.
    Poulin-Costello, M.
    Walker, V
    Haraoui, B.
    VALUE IN HEALTH, 2016, 19 (03) : A229 - A230
  • [8] Down-titration and discontinuation of infliximab in rheumatoid arthritis patients with stable low disease activity and stable treatment: an observational cohort study
    van der Maas, Aatke
    Kievit, Wietske
    van den Bemt, Bart J. F.
    van den Hoogen, Frank H. J.
    van Riel, Piet L.
    den Broeder, Alfons A.
    ANNALS OF THE RHEUMATIC DISEASES, 2012, 71 (11) : 1849 - 1854
  • [9] ACHIEVEMENT OF LOW DISEASE ACTIVITY IN PATIENTS INITIATING INFLIXIMAB WITH AND WITHOUT DOSE ESCALATION
    Cohen, S.
    Reed, G.
    Magner, R.
    Kafka, S.
    Ellis, L.
    DeHoratius, R. J.
    Greenberg, J. D.
    ANNALS OF THE RHEUMATIC DISEASES, 2016, 75 : 238 - 239
  • [10] Infliximab dose escalation in patients with rheumatoid arthritis in the START study: Influence of Infliximab pharmacokinetics and immunogenicity
    Rahman, M. U.
    Strusberg, I.
    Geusens, P.
    Wagner, C.
    Han, J.
    Westhovens, R.
    ZEITSCHRIFT FUR RHEUMATOLOGIE, 2007, 66 : 86 - 86
12345